BenQ Medical Technology (4116) — Cash Flow Reinvestment Rate
BenQ Medical Technology (4116) has a Cash Flow Reinvestment Rate of 0.42x as of June 2025, reinvesting NT$76.10 Million (capex NT$14.79 Million plus investments NT$-61.31 Million) from operating cash flow of NT$179.07 Million. Check 4116 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
BenQ Medical Technology Cash Flow Reinvestment Rate (2017–2024)
Historical reinvestment intensity for BenQ Medical Technology across 8 annual periods. Explore 4116 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for BenQ Medical Technology (2017–2024)
Year-by-year capital reinvestment analysis for BenQ Medical Technology. For live market cap and broader valuation context, see BenQ Medical Technology (4116) total market value.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.88x | NT$195.80 Million | NT$222.22 Million | NT$175.48 Million | ▲ +45.5% |
| 2023 | 0.61x | NT$267.96 Million | NT$442.35 Million | NT$139.28 Million | ▲ +39.9% |
| 2022 | 0.43x | NT$164.04 Million | NT$378.77 Million | NT$60.05 Million | ▼ -45.2% |
| 2021 | 0.79x | NT$95.91 Million | NT$121.35 Million | NT$32.92 Million | ▲ +54.4% |
| 2020 | 0.51x | NT$77.53 Million | NT$151.48 Million | NT$42.37 Million | ▲ +205.9% |
| 2019 | 0.17x | NT$28.32 Million | NT$169.23 Million | NT$21.15 Million | ▼ -57.1% |
| 2018 | 0.39x | NT$49.21 Million | NT$126.10 Million | NT$31.36 Million | ▼ -77.9% |
| 2017 | 1.77x | NT$128.91 Million | NT$72.97 Million | NT$112.31 Million | — |